{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:21:41Z","timestamp":1794720101257,"version":"4.9.1"},"reference-count":14,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Nintedanib is approved for the treatment of interstitial lung disease (ILD) with progressive pulmonary fibrosis (PPF). Real-life data on nintedanib treatment for this indication and on the combined use of antifibrotic and immunomodulatory drugs are limited. This study was aimed to collect detailed real-life data from all patients with non-idiopathic pulmonary fibrosis (IPF) PPF at the Hospital District of Helsinki and Uusimaa to identify the gap between patients included in randomised controlled trials and real-life patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>This retrospective, real-life study characterised all patients with non-IPF PPF diagnosed and treated at the Hospital District of Helsinki and Uusimaa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Thirty-one patients were identified as having non-IPF fibrotic ILD and meeting the PPF criteria in 2022 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most common diagnosis was connective tissue disease\u2013ILDs, with 13 patients (42%), followed by fibrotic idiopathic non-specific interstitial pneumonia (iNSIP), with 10 (32%) patients. The most common radiological pattern was NSIP in 18 (58%) patients.<\/jats:p>\n                    <jats:p>Among the 30 patients treated with nintedanib, six (20%) had to permanently discontinue treatment owing to side effects. Of the 19 patients who continued to receive nintedanib at the end of the follow-up period and for whom the dose was known, 9 (47%) continued to receive nintedanib at the full dose (150\u2009mg two times per day) and 10 (53%) at the reduced dose (100\u2009mg two times per day). Twenty-seven (87%) patients received immunomodulatory treatment at the time of PPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our cohort, the underlying diagnoses and immunomodulatory treatments received significantly differed from those in the phase III licensing trial. More patients received nintedanib at a reduced dose than at a full dose, despite limited evidence of its efficacy and effectiveness. This highlights the large gap in evidence and the need for additional real-world data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097246","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:44:34Z","timestamp":1762263874000},"page":"e097246","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Characterisation of patients with antifibrotic-treated non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis: a retrospective real-life study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-5433","authenticated-orcid":false,"given":"Andreas","family":"Renner","sequence":"first","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Department of Pneumology, Medical University of Vienna, Wien, Austria"},{"name":"Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9884-2001","authenticated-orcid":false,"given":"Elisa","family":"Vertanen","sequence":"additional","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sutinen","sequence":"additional","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Department of Pulmonology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-5851","authenticated-orcid":false,"given":"Mari","family":"Ainola","sequence":"additional","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Department of Pulmonology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Myll\u00e4rniemi","sequence":"additional","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Department of Pulmonology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hollm\u00e9n","sequence":"additional","affiliation":[{"name":"Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"Department of Pulmonology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026111421151444000_15.11.e097246.1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"key":"2026111421151444000_15.11.e097246.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026111421151444000_15.11.e097246.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026111421151444000_15.11.e097246.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026111421151444000_15.11.e097246.5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"2026111421151444000_15.11.e097246.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026111421151444000_15.11.e097246.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201184"},{"key":"2026111421151444000_15.11.e097246.8","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00597-2021","article-title":"Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries","volume":"8","author":"Hilberg","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026111421151444000_15.11.e097246.9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123229","article-title":"Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience","volume":"10","author":"Levra","year":"2022","journal-title":"Biomedicines"},{"key":"2026111421151444000_15.11.e097246.10","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.rmed.2019.105803","article-title":"Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment","volume":"159","author":"Cerri","year":"2019","journal-title":"Respir Med"},{"key":"2026111421151444000_15.11.e097246.11","doi-asserted-by":"crossref","unstructured":"Rahaghi F , Belperio JA , Fitzgerald J , et al . Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clin Med Insights Circ Respir Pulm Med 2021;15. doi:10.1177\/11795484211006050","DOI":"10.1177\/11795484211006050"},{"key":"2026111421151444000_15.11.e097246.12","doi-asserted-by":"crossref","first-page":"107015","DOI":"10.1016\/j.rmed.2022.107015","article-title":"Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis","volume":"204","author":"Porse","year":"2022","journal-title":"Respir Med"},{"key":"2026111421151444000_15.11.e097246.13","doi-asserted-by":"crossref","unstructured":"Ruaro B , Salotti A , Reccardini N , et al . n.d. Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study. Pharmaceuticals (Basel) 17:119. doi:10.3390\/ph17010119","DOI":"10.3390\/ph17010119"},{"key":"2026111421151444000_15.11.e097246.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:15:32Z","timestamp":1794719732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2024-097246"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097246","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097246.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}